Boston Immune Technologies & Therapeutics

Executive Summary

Boston Immune Technologies & Therapeutics (BITT) is a private biotechnology company headquartered in Boston, Massachusetts, founded in 2017. The company is developing a proprietary platform of monoclonal antibodies called TrapMAbs, which are designed to antagonize members of the Tumor Necrosis Factor Receptor (TNFR) superfamily. BITT's pipeline is focused on applying these antagonists to both oncology and autoimmune/inflammatory diseases, aiming to modulate immune responses with high specificity and reduced toxicity. As a privately held company with no disclosed funding rounds or valuation, BITT operates in a highly competitive space, but its unique TrapMAb technology could offer advantages over existing TNFR-targeted therapies. The company has not yet advanced any candidates to clinical trials, and its progress is primarily at the preclinical stage.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical data for lead TrapMAb program30% success
• Q4 2026Announcement of series A financing or strategic partnership40% success
• Q2 2027IND filing for first oncology candidate15% success